Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine
March 28 2023 - 5:00AM
Business Wire
- A Bill & Melinda Gates Foundation grant will be used to
expand research and development of OVX836 in a wide range of
seasonal and highly pathogenic influenza strains
- Osivax continues evaluating OVX836 across several phase 2
clinical trials in healthy volunteers
Osivax, a biopharmaceutical company developing vaccines to
provide broad-spectrum protection against highly mutating
infectious viruses, today announced that it has received a global
pneumonia and pandemic preparedness grant of over USD 1M from the
Bill & Melinda Gates Foundation to support additional research
and development of its lead, broad-spectrum influenza vaccine
candidate, OVX836.
Osivax will use the grant to evaluate the breadth and the
duration of protection provided by OVX836 against a wider range of
seasonal and highly pathogenic influenza strains. This research
will assess the potential of OVX836 to provide long-term protection
against emerging and circulating strains of influenza thus
informing its potential as a standalone influenza vaccine
administered less frequently than annually.
Alexandre Le VERT, CEO of Osivax commented, “This support
from the Bill & Melinda Gates Foundation will allow us to widen
the scope of OVX863’s development and brings us one step closer to
providing much needed, universal protection against both seasonal
and pandemic influenza strains, which continue posing a significant
global health threat. We are incredibly grateful to the Bill &
Melinda Gates Foundation for their support in the research and
development of OVX836, as this will allow us to better understand
its potential application across the world, particularly in
developing countries.”
OVX836 has shown promising safety, immunogenicity and efficacy
data across preclinical and clinical trials (Phase 1 and Phase 2a)
and continues being evaluated in additional studies. Osivax
recently announced the Last Patient Last Visit (LPLV) in two Phase
2a clinical trials evaluating OVX836: a dose-optimization study
(OVX836-003) in Belgium, extended to include elderly participants
aged 65 years and older, and a co-administration study conducted in
Australia (OVX836-004) with OVX836 and a quadrivalent inactivated
influenza virus (QIV) vaccine.
More information on the grant can be found at the following
website.
About OVX836 OVX836 is a first-in-class influenza vaccine
candidate that targets the nucleoprotein (NP), a highly conserved
internal antigen. Unlike surface antigens, the NP is much less
likely to mutate, providing a broader and more universal immune
response. Osivax’ oligoDOM® technology enables the design and
production of a recombinant version of the NP which self-assembles
into a nanoparticle, thus triggering powerful T- and B-cell immune
responses. OVX836 has been tested in 4 clinical trials with 800
participants so far, and has shown promising safety,
immunogenicity, and efficacy read-outs.
About Osivax Osivax is a biopharmaceutical company
leveraging its novel, self-assembling nanoparticle platform
technology, oligoDOM®, to transform current and new vaccines
against highly mutating viruses by generating superior T-cell
responses in addition to strong and sustained B-cell responses. The
company is establishing proof of concept with its broad-spectrum
“universal” influenza candidate, OVX836, which is currently in
Phase 2 clinical trials with over 800 subjects tested. Osivax’
ambition is to develop a pan-respiratory virus vaccine to prevent
all strains of influenza and all variants of Covid-19 in one single
shot. The company will expand into other infectious disease
indications through combinations and collaborations worldwide.
For further information: www.osivax.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230328005114/en/
Alexandre Le Vert, CEO contact@osivax.com +33 (0) 9 70 30 13
80
For Media Inquiries Trophic Communications Valeria Fisher
or Desmond James Osivax@trophic.eu +49 (0) 175 804 1816 or +49 (0)
151 678 59086